Demonstrates longer progression-free survival with nivolumab plus AVD in advanced-stage classic Hodgkin lymphoma, indicating a superior first-line regimen.
N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.).
No takes yet. Share an insight, caveat, or question.
Herrera et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: